Clinical trials: pMN, open to volunteers
Asthma, COPD
Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections.
- Conditions
- Asthma, COPD, Bacterial Pneumonia, Viral Pneumonia
- Trial name
- OXIGENE (NCT07386912)
- Testing
- Characterization of the neutrophil granulocyte epigenome, Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Research Center Borstel
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Neuroblastoma
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response.
- Trial name
- NCT06047535
- Testing
- Naxitamab
- Volunteers
- 62 people
- Sponsor
- SciClone Pharmaceuticals
Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
- Trial name
- PrisMN (NCT07096843)
- Testing
- budoprutug
- Where
- 38 sites in United States, Argentina and 5 more
- Volunteers
- 45 people
- Sponsor
- Climb Bio, Inc.
Stem Cell Transplant Complications
Loratadine for the Prevention of G-CSF-related Bone Pain
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma?…
- Trial name
- NCT05421416
- Testing
- Loratadine
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- AHS Cancer Control Alberta
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney.
- Trial name
- PROMINENT (NCT06962800)
- Testing
- Felzartamab, Tacrolimus, Standard of Care IST
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Biogen
Plasma Cell Myeloma
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization.
- Trial name
- NCT04211259
- Testing
- Loratadine, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Rutgers, The State University of New Jersey
Hematologic Malignancies
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
This trial is a prospective, single-arm, single-center clinical study. A total of 44 elderly (aged 60 to 69 years) patients with hematological malignancies who need to receive a single-unit unrelated umbilical cord blood…
- Trial name
- NCT07441967
- Testing
- Thiotepa, Fludarabine, G-CSF
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to…
- Trial name
- NCT06536010
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Xiaotian
DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly…
- Trial name
- NCT07749365
- Testing
- hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
National and international guidelines/consensus recommend G-CSF (granulocyte colony-stimulating factor) at 10 μg/kg/day as a single daily dose or divided into two daily doses for mobilization in healthy donors for allogeneic…
- Trial name
- NCT07692841
- Testing
- Single-dose Granulocyte colony-stimulating factor (G-CSF), Divided-dose Granulocyte colony-stimulating factor (G-CSF)
- Where
- 8 sites in China
- Volunteers
- 560 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Granuloma, Granulomatous Disease, Chronic
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marrow, and Mononuclear Cells (lymphocytes and monocytes), and granulocytes (grans) from peripheral blood that…
- Conditions
- Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked
- Trial name
- NCT00001405
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by…
- Conditions
- Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia, Autoimmune Neutropenia, Chronic Idiopathic Neutropenia
- Trial name
- NCT07902830
- Testing
- Mavorixafor
- Volunteers
- 40 people
- Sponsor
- X4 Pharmaceuticals
Cerebral Edema, Ischemic Stroke, Acute
A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke
The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke.
- Conditions
- Cerebral Edema, Ischemic Stroke, Acute, Malignant Cerebral Edema, Anterior Circulation Brain Infarction
- Trial name
- NCT07386262
- Testing
- Adacolumn®, Standard Reperfusion Therapy, Standard Medical Management
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
High-Risk Neuroblastoma
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.
- Trial name
- NCT07537400
- Testing
- Naxitamab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Shaare Zedek Medical Center
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.
Allogeneic Granulocyte Donation
Improving White Blood Cell Collection From Healthy Donors
Background: White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells.
- Trial name
- NCT01553214
- Testing
- Filgrastim, Dexamethasone
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
- Trial name
- NCT06216938
- Testing
- Vusolimogene oderparepvec (RP1)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yana Najjar
Cervical Cancer
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer.
- Trial name
- NCT05817214
- Testing
- Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhongnan Hospital